283 related articles for article (PubMed ID: 31707823)
1. Net Clinical Benefit of Oral Anticoagulation Among Older Adults With Atrial Fibrillation.
Shah SJ; Singer DE; Fang MC; Reynolds K; Go AS; Eckman MH
Circ Cardiovasc Qual Outcomes; 2019 Nov; 12(11):e006212. PubMed ID: 31707823
[TBL] [Abstract][Full Text] [Related]
2. Age-Related Differences in the Clinical Characteristics and Treatment of Elderly Patients With Atrial Fibrillation in Japan - Insight From the ANAFIE (All Nippon AF In Elderly) Registry.
Hiasa KI; Kaku H; Inoue H; Yamashita T; Akao M; Atarashi H; Koretsune Y; Okumura K; Shimizu W; Ikeda T; Toyoda K; Hirayama A; Yasaka M; Yamaguchi T; Teramukai S; Kimura T; Kaburagi J; Takita A; Tsutsui H
Circ J; 2020 Feb; 84(3):388-396. PubMed ID: 31969518
[TBL] [Abstract][Full Text] [Related]
3. Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
Falissard B; Picard F; Mahe I; Hanon O; Touzé E; Danchin N; Lamy FX; Ricci L; Steg PG
Arch Cardiovasc Dis; 2019; 112(6-7):400-409. PubMed ID: 31014991
[TBL] [Abstract][Full Text] [Related]
4. Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States.
Siontis KC; Zhang X; Eckard A; Bhave N; Schaubel DE; He K; Tilea A; Stack AG; Balkrishnan R; Yao X; Noseworthy PA; Shah ND; Saran R; Nallamothu BK
Circulation; 2018 Oct; 138(15):1519-1529. PubMed ID: 29954737
[TBL] [Abstract][Full Text] [Related]
5. Net clinical benefit of warfarin in individuals with atrial fibrillation across stroke risk and across primary and secondary care.
Allan V; Banerjee A; Shah AD; Patel R; Denaxas S; Casas JP; Hemingway H
Heart; 2017 Feb; 103(3):210-218. PubMed ID: 27580623
[TBL] [Abstract][Full Text] [Related]
6. Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy.
Lip GY; Skjøth F; Nielsen PB; Larsen TB
Thromb Haemost; 2015 Oct; 114(4):826-34. PubMed ID: 26223245
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation.
Di Biase L; Callans D; Hæusler KG; Hindricks G; Al-Khalidi H; Mont L; Cosedis Nielsen J; Piccini JP; Schotten U; Kirchhof P
Europace; 2017 Jan; 19(1):132-138. PubMed ID: 28130378
[TBL] [Abstract][Full Text] [Related]
8. Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study.
Rutherford OW; Jonasson C; Ghanima W; Söderdahl F; Halvorsen S
Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):75-85. PubMed ID: 31942972
[TBL] [Abstract][Full Text] [Related]
9. Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial.
Pol T; Held C; Westerbergh J; Lindbäck J; Alexander JH; Alings M; Erol C; Goto S; Halvorsen S; Huber K; Hanna M; Lopes RD; Ruzyllo W; Granger CB; Hijazi Z
J Am Heart Assoc; 2018 Feb; 7(3):. PubMed ID: 29419390
[TBL] [Abstract][Full Text] [Related]
10. Secondary stroke prevention with apixaban in nonvalvular atrial fibrillation: A subgroup analysis of the STANDARD study.
Yasaka M; Umeyama M; Kataoka H; Inoue H
J Stroke Cerebrovasc Dis; 2020 Sep; 29(9):105034. PubMed ID: 32807446
[TBL] [Abstract][Full Text] [Related]
11. A multicenter prospective cohort study to investigate the effectiveness and safety of apixaban in Japanese elderly atrial fibrillation patients (J-ELD AF Registry).
Okumura K; Yamashita T; Suzuki S; Akao M;
Clin Cardiol; 2020 Mar; 43(3):251-259. PubMed ID: 31737921
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
[TBL] [Abstract][Full Text] [Related]
13. Net clinical benefit of edoxaban versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study.
Blann AD; Banerjee A; Lane DA; Torp-Pedersen C; Lip GY
Int J Cardiol; 2015 Dec; 201():693-8. PubMed ID: 26379097
[TBL] [Abstract][Full Text] [Related]
14. Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial.
van Nieuwenhuizen KM; van der Worp HB; Algra A; Kappelle LJ; Rinkel GJ; van Gelder IC; Schutgens RE; Klijn CJ;
Trials; 2015 Sep; 16():393. PubMed ID: 26340977
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia.
Hersi AS; Osenenko KM; Kherraf SA; Aziz AA; Sambrook RJ
Ann Saudi Med; 2019; 39(4):265-278. PubMed ID: 31381381
[TBL] [Abstract][Full Text] [Related]
16. Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study.
Picard F; Ducrocq G; Danchin N; Falissard B; Hanon O; Mahe I; Touzé E; Steg PG
Arch Cardiovasc Dis; 2018 May; 111(5):349-356. PubMed ID: 29191525
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial.
Halvorsen S; Atar D; Yang H; De Caterina R; Erol C; Garcia D; Granger CB; Hanna M; Held C; Husted S; Hylek EM; Jansky P; Lopes RD; Ruzyllo W; Thomas L; Wallentin L
Eur Heart J; 2014 Jul; 35(28):1864-72. PubMed ID: 24561548
[TBL] [Abstract][Full Text] [Related]
18. Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial.
Cowper PA; Sheng S; Lopes RD; Anstrom KJ; Stafford JA; Davidson-Ray L; Al-Khatib SM; Ansell J; Dorian P; Husted S; McMurray JJV; Steg PG; Alexander JH; Wallentin L; Granger CB; Mark DB
JAMA Cardiol; 2017 May; 2(5):525-534. PubMed ID: 28355434
[TBL] [Abstract][Full Text] [Related]
19. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation.
Bahit MC; Lopes RD; Wojdyla DM; Held C; Hanna M; Vinereanu D; Hylek EM; Verheugt F; Goto S; Alexander JH; Wallentin L; Granger CB
Heart; 2017 Apr; 103(8):623-628. PubMed ID: 27798052
[TBL] [Abstract][Full Text] [Related]
20. Apixaban versus No Anticoagulation in Patients Undergoing Long-Term Dialysis with Incident Atrial Fibrillation.
Mavrakanas TA; Garlo K; Charytan DM
Clin J Am Soc Nephrol; 2020 Aug; 15(8):1146-1154. PubMed ID: 32444398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
